
Specific US stock market data for today is temporarily unavailable, but capital rotation and the valuation resetting of disruptive innovation sectors are ongoing processes.

--
--
--
Cathie Wood's overall trading logic for the day suggests a strategy of leaving the weak and staying with the strong, reallocating capital toward precision medicine and gene editing backed by foundational logic, while adjusting certain tech and blockchain positions for liquidity management.
Buy: Heavy bets on precision medicine and gene editing, moderate additions to tech giants
Bought $Beam Therapeutics (BEAM.US)$ 102,565 shares. As a pioneer in gene editing with a deep moat in base editing technology, this move likely reflects a long-term bullish outlook and strategic addition to the foundational logic of precision medicine.
Bought $Ionis Pharmaceuticals (IONS.US)$ 100,241 shares. The company boasts a rich pipeline in RNA-targeted therapies, and this addition may indicate positive expectations for its R&D and commercialization progress.
Bought $Veracyte (VCYT.US)$ 74,878 shares. As a disruptor in the diagnostics space with high-barrier genomic testing technologies, this is presumably a bet on the long-term growth potential in the precision diagnostics sector.
Bought $Scribe Therapeutics (SCTX.US)$ 61,858 shares. Focusing on CRISPR gene editing platform innovation, this positioning might be aimed at capturing valuation resetting opportunities in next-generation gene therapies.
Bought $Meta Platforms (META.US)$ 51,477 shares. As a tech giant in AI and social media with a strong moat in advertising monetization and underlying AI tech, this is likely a defensive allocation seeking core assets.
Bought $Airbnb (ABNB.US)$ 29,587 shares. The sharing economy model has unique platform effects, and this addition may reflect a favor for its long-term free cash flow and network effect expansion.
Sell: Balancing precision medicine positions, moderate adjustments to blockchain and cybersecurity
Sold $Everpure (P.US)$ 59,265 shares. This could be due to excessive short-term valuation premiums or changing industry competitive landscapes, executing position rebalancing and capital reallocation.
Sold $10x Genomics (TXG.US)$ 32,284 shares. With intensifying competition in single-cell technology, this reduction might be aimed at lowering the concentration risk of this target within the precision medicine portfolio.
Sold $ARK 21Shares Bitcoin ETF (ARKB.US)$ 29,705 shares. Considering recent market volatility in crypto assets, this move could be part of liquidity management, moderately reducing exposure to this asset class.
Sold $CrowdStrike (CRWD.US)$ 28,403 shares. While the cybersecurity sector holds long-term value, this reduction may reflect sector rotation, shifting capital from high-valuation targets to more core innovation sectors.
Sold $Twist Bioscience (TWST.US)$ 12,536 shares. Synthetic biology faces short-term growth pressures, and this action might be based on risk control, adjusting positions to leave the weak and stay with the strong.
Go to Markets> Smart Money Tracker to track Cathie Wood's portfolio. Tap "Alerts" to receive real-time buy and sell signals. Update the app to try it now>>

Disclaimer: Moomoo Technologies Inc. is providing this content for information and educational use only.Read more
Comments
to post a comment
9
1
